Current Clinical Trials
General Search Sites
ClinicalTrials.gov hosts a comprehensive listing of clinical trials being conducted in the United States and around the world. The site allows you to search for Clinical Trials that may be appropriate for you or a loved one. ClinicalTrials.gov gives you information about a trial’s purpose, who may participate, locations, and phone numbers for more details.
The WAPC Clinical Trials Resource Center, presented in partnership with CenterWatch, hosts a detailed listing of clinical trials, studies at the National Institutes of Health and an email notification service to be alerted when new prostate cancer clinical trials are posted to the database.
Prostate Cancer Clinical Trials (please note this is not an exhaustive list, please visit clinicaltrials.gov for a complete listing):
Janssen Biotech, Inc. is sponsoring an advanced prostate cancer research study. This study will evaluate the effectiveness of an investigational drug plus prednisone to determine if there is a decrease in Prostate-Specific Antigen (PSA). The study will also evaluate whether this combination prolongs the time until it is evident that the cancer has spread. Additionally, safety information will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last. You may be eligible for the study if you:
- Are eighteen years of age or older
- Have been diagnosed with prostate cancer
- Are currently receiving, and have had continuous therapy with, Gonadotropin-releasing hormone (GnRH) monotherapy for at least 6 months or have undergone surgical removal of the testicles
To learn more about this study, please visit www.prostatecancerstudynow.com
The PREVAIL Trial is a Phase 3 clinical trial. It will test the effects of an oral investigational drug called MDV3100 in men with advanced prostate cancer that continues to progress despite hormonal therapy. The purpose of the trial is to determine whether this investigational prostate cancer therapy can safely slow the progression of the disease and extend the lives of men with prostate cancer.
Men whose prostate cancer fits this description may be able to join the PREVAIL Trial:
- Your cancer has spread beyond the prostate.
- Your cancer has progressed despite hormonal therapy.
- Your cancer causes no pain or mild pain.
- Your cancer has not been treated with chemotherapy.
Please call 888-243-4363 in the US and Canada for information about being part of the PREVAIL Trial if you meet the entry requirements and live near or can travel to one of the clinical trial locations.
If you have been diagnosed with prostate cancer, you may wonder how you and your partner will manage this experience. The Telephone Education and Support Project is designed to help men and their partners during the prostate cancer experience. They will call you on the telephone throughout your participation in this study to discuss questions or issues that are of concern to you.
You might be eligible to participate in this study if:
- You have been diagnosed with prostate cancer
- You are currently receiving treatment
- You are over 21 years of age.
- You have a partner, friend or relative who would participate or you are a partner, friend or relative of a man with prostate cancer.
To speak to someone about this study, the Telephone Education and Support Project, or to enroll, please contact:
Terry Badger, PhD, RN
Professor, College of Nursing
Phone: (520) 626-6058
Toll free: 1-866-218-6641
Cell phone: (520) 730-7455
The purpose of this study is to collect additional safety information on abiraterone acetate administered with prednisone to patients with metastatic castration-resistant prostate cancer (CRPC).
There are currently 53 study locations. To see a list of the locations and view criteria for the study, click here.
A Phase 3 registration trial of custirsen, referred to as the SYNERGY trial, is being conducted by OncoGenex Pharmaceuticals in collaboration with Teva Pharmaceuticals. This randomized, controlled, international Phase 3 trial will enroll approximately 800 men with castrate-resistant prostate cancer who have disease progression and require first-line docetaxel chemotherapy.
For more information about the SYNERGY trial click here
An investigator-sponsored phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate-resistant prostate cancer. The randomized, controlled phase 2 study is designed to determine the potential benefit of OGX-427 by evaluating the number of patients who are without disease progression at 12 weeks post study treatment with or without OGX-427. This phase 2 trial will also measure the direct effect of OGX-427 on PSA levels, time to progression by PSA or measurable disease, numbers of CTCs and other relevant secondary endpoints. This investigator-sponsored study is supported by the British Columbia Cancer Agency (“BCCA”).
Click here for more information on this trial.